Or are its best days in the rearview mirror?

Axsome Therapeutics verzeichnet Kursgewinne dank starker Daten für Auvelity, das zur Behandlung von Alzheimer-assoziierten ...

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a ...

The stock slipped about 15% over the past three months.

Axsome Therapeutics (NasdaqGM:AXSM) reported new clinical data in major depressive disorder and Alzheimer’s disease agitation at a leading psychiatry congress. The presentations focused on key ...

Nachrichten zur Vonovia Axsome Therapeutics Aktie - Aktuelle Meldungen - Das sind die Expertenmeinungen des Monats September ...

Auf der Citizens Life Sciences Conference am 10. März unterstrich das Management die operativen Fortschritte. Das Medikament Auvelity entwickelte sich im vergangenen Geschäftsjahr zum klaren ...

Axsome Therapeutics erwirbt von Takeda den fortgeschrittenen Wirkstoffkandidaten Balipodect zur Behandlung von Schizophrenie und Tourette-Syndrom. Die Phase-3-Studien sollen noch 2026 starten. Axsome ...

Axsome Therapeutics has made significant clinical and regulatory progress over the past few years. The company earned approval for Auvelity as a treatment for depression, and more recently won a label ...

As we can see, Axsome's primary focus is on central nervous system ("CNS") diseases, and it has three approved products across four CNS indications: major depressive disorder ("MDD"), agitation ...

Amgen discovers and delivers medicines for serious diseases across several core areas, including inflammation, rare disease, and oncology. Its massive scale allows it to distribute products to roughly ...